KR102050463B1 - 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 - Google Patents

항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR102050463B1
KR102050463B1 KR1020170101594A KR20170101594A KR102050463B1 KR 102050463 B1 KR102050463 B1 KR 102050463B1 KR 1020170101594 A KR1020170101594 A KR 1020170101594A KR 20170101594 A KR20170101594 A KR 20170101594A KR 102050463 B1 KR102050463 B1 KR 102050463B1
Authority
KR
South Korea
Prior art keywords
region
cells
ser
domain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170101594A
Other languages
English (en)
Korean (ko)
Other versions
KR20180018419A (ko
Inventor
김용성
정근옥
하지희
최혜지
김예진
최동기
Original Assignee
아주대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아주대학교산학협력단 filed Critical 아주대학교산학협력단
Priority to JP2019506697A priority Critical patent/JP6993403B2/ja
Priority to BR112019002394-1A priority patent/BR112019002394B1/pt
Priority to US16/323,839 priority patent/US10696722B2/en
Priority to AU2017310163A priority patent/AU2017310163B2/en
Priority to CA3033475A priority patent/CA3033475A1/en
Priority to SG11201901071TA priority patent/SG11201901071TA/en
Priority to MX2019001651A priority patent/MX386014B/es
Priority to PCT/KR2017/008676 priority patent/WO2018030806A1/ko
Publication of KR20180018419A publication Critical patent/KR20180018419A/ko
Priority to ZA2019/00772A priority patent/ZA201900772B/en
Priority to IL264692A priority patent/IL264692B2/en
Priority to MX2021010809A priority patent/MX2021010809A/es
Priority to KR1020190152270A priority patent/KR102416411B1/ko
Application granted granted Critical
Publication of KR102050463B1 publication Critical patent/KR102050463B1/ko
Priority to US16/886,177 priority patent/US11078249B2/en
Priority to US16/886,184 priority patent/US11692019B2/en
Priority to JP2021033816A priority patent/JP7111855B2/ja
Priority to AU2021273642A priority patent/AU2021273642B2/en
Priority to JP2022116329A priority patent/JP7488854B2/ja
Priority to US18/323,124 priority patent/US12358964B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020170101594A 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 Active KR102050463B1 (ko)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2019506697A JP6993403B2 (ja) 2016-08-10 2017-08-10 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
BR112019002394-1A BR112019002394B1 (pt) 2016-08-10 2017-08-10 Proteína heterodimérica fundida com fc e seu uso
US16/323,839 US10696722B2 (en) 2016-08-10 2017-08-10 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
AU2017310163A AU2017310163B2 (en) 2016-08-10 2017-08-10 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
CA3033475A CA3033475A1 (en) 2016-08-10 2017-08-10 Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
SG11201901071TA SG11201901071TA (en) 2016-08-10 2017-08-10 Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
MX2019001651A MX386014B (es) 2016-08-10 2017-08-10 Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
PCT/KR2017/008676 WO2018030806A1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
ZA2019/00772A ZA201900772B (en) 2016-08-10 2019-02-06 Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
IL264692A IL264692B2 (en) 2016-08-10 2019-02-06 Heterodimeric cytokine fused to FC and pharmaceutical preparation containing the same
MX2021010809A MX2021010809A (es) 2016-08-10 2019-02-08 Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma.
KR1020190152270A KR102416411B1 (ko) 2016-08-10 2019-11-25 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US16/886,177 US11078249B2 (en) 2016-08-10 2020-05-28 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US16/886,184 US11692019B2 (en) 2016-08-10 2020-05-28 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
JP2021033816A JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
AU2021273642A AU2021273642B2 (en) 2016-08-10 2021-11-26 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
JP2022116329A JP7488854B2 (ja) 2016-08-10 2022-07-21 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
US18/323,124 US12358964B2 (en) 2016-08-10 2023-05-24 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160101823 2016-08-10
KR20160101823 2016-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020190152270A Division KR102416411B1 (ko) 2016-08-10 2019-11-25 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20180018419A KR20180018419A (ko) 2018-02-21
KR102050463B1 true KR102050463B1 (ko) 2019-11-29

Family

ID=61524969

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020170101594A Active KR102050463B1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR1020190152270A Active KR102416411B1 (ko) 2016-08-10 2019-11-25 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR1020220079686A Active KR102607285B1 (ko) 2016-08-10 2022-06-29 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR1020230164332A Active KR102652247B1 (ko) 2016-08-10 2023-11-23 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020190152270A Active KR102416411B1 (ko) 2016-08-10 2019-11-25 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR1020220079686A Active KR102607285B1 (ko) 2016-08-10 2022-06-29 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR1020230164332A Active KR102652247B1 (ko) 2016-08-10 2023-11-23 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물

Country Status (14)

Country Link
US (4) US10696722B2 (enExample)
EP (2) EP4470552A3 (enExample)
JP (3) JP6993403B2 (enExample)
KR (4) KR102050463B1 (enExample)
CN (1) CN110267977A (enExample)
AU (2) AU2017310163B2 (enExample)
BR (1) BR112019002394B1 (enExample)
CA (1) CA3033475A1 (enExample)
DK (1) DK3511340T3 (enExample)
ES (1) ES3000558T3 (enExample)
IL (1) IL264692B2 (enExample)
MX (2) MX386014B (enExample)
SG (1) SG11201901071TA (enExample)
ZA (1) ZA201900772B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098108A (ko) * 2016-08-10 2022-07-11 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069105A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
KR102285557B1 (ko) 2018-02-14 2021-08-04 주식회사 엘지화학 촉매의 충진방법 및 이를 이용한 부타디엔의 제조방법
CN110396133B (zh) * 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CA3157024A1 (en) * 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
IL297495A (en) * 2020-04-22 2022-12-01 Dragonfly Therapeutics Inc Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins
JP2024500354A (ja) 2020-12-10 2024-01-09 インベンラ， インコーポレイテッド ヘテロ二量体化のための直交変異
AU2022369312A1 (en) * 2021-10-20 2024-05-02 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
CN119768414A (zh) * 2022-11-10 2025-04-04 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用
WO2024249320A1 (en) * 2023-05-26 2024-12-05 University Of Florida Research Foundation, Incorporated In vivo optimization of biologics
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015089A1 (en) * 1997-12-08 2010-01-21 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2014084607A1 (ko) 2012-11-27 2014-06-05 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20020055488A1 (en) 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
WO2005114186A1 (ja) 2004-05-20 2005-12-01 Wako Pure Chemical Industries, Ltd. ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US8163498B2 (en) 2006-08-08 2012-04-24 Seikagaku Corporation Method for determination of molecular weight of hyaluronic acid
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2399584T3 (es) 2008-04-15 2013-04-02 Wako Pure Chemical Industries, Ltd. Nueva proteína capaz de unirse al ácido hialurónico y procedimiento para medir el ácido hialurónico usando la misma
BRPI1007005A2 (pt) 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PL2714718T3 (pl) 2011-05-24 2017-11-30 Symic Ip, Llc Syntetyczne peptydoglikany wiążące kwas hialuronowy, otrzymywanie i sposoby zastosowania
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CA3101783C (en) 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS CONTAINING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMERMOLUCKS FOR HYALURONIC ACIDIC TREATMENT AND TISSUE RENEWAL APPLICATIONS
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
KR20150038511A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 불활성 면역글로불린 Ｆｃ-영역을 갖는 Ｆｃ-융합체로서의 가용성 ＦｃＲ 의 생산 방법 및 그의 용도
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
AU2013301582B2 (en) 2012-08-07 2018-09-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
EA035645B1 (ru) 2013-03-15 2020-07-21 Дженентек, Инк. ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970435B1 (en) 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2955736T3 (es) 2014-05-06 2023-12-05 Hoffmann La Roche Producción de proteínas heteromultiméricas usando células de mamífero
KR101721295B1 (ko) 2014-06-11 2017-04-10 주식회사 엘지화학 염화비닐계 수지의 제조방법
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
EP3215524B1 (en) 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
JP6898303B2 (ja) 2015-08-07 2021-07-07 エーエルエックス オンコロジー インコーポレイテッド Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物
CA3001185A1 (en) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Nk engaging compounds and methods
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
ES3000558T3 (en) 2016-08-10 2025-02-28 Univ Ajou Ind Academic Coop Found Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
AU2018241624B2 (en) 2017-03-27 2024-01-25 F. Hoffmann-La Roche Ag Improved antigen binding receptors
CA3062519A1 (en) 2017-05-11 2018-11-15 Emd Millipore Corporation Method of maintaining narrow residence time distributions in continuous flow systems using solid material packet interfaces
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US11426706B2 (en) 2017-06-21 2022-08-30 Cephalon, Inc. Cation exchange chromatography wash buffer
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
CN113004417A (zh) 2017-09-07 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111132997A (zh) 2017-09-21 2020-05-08 默克专利有限公司 包含fgf-18部分的融合蛋白
MY202919A (en) 2017-09-22 2024-05-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
CN111246885B (zh) 2017-10-20 2024-06-11 豪夫迈·罗氏有限公司 从单特异性抗体生成多特异性抗体的方法
BR112021000392A2 (pt) 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015089A1 (en) * 1997-12-08 2010-01-21 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2014084607A1 (ko) 2012-11-27 2014-06-05 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
최혜지 아주대학교 박사학위논문(Development of heterodimeric Fc variants for bispecific antibody platform technology); 2015. 8.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098108A (ko) * 2016-08-10 2022-07-11 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR102607285B1 (ko) * 2016-08-10 2023-12-01 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2017310163B2 (en) 2021-09-09
KR20180018419A (ko) 2018-02-21
JP6993403B2 (ja) 2022-03-03
JP2019536734A (ja) 2019-12-19
US20190169252A1 (en) 2019-06-06
JP7111855B2 (ja) 2022-08-02
EP3511340B1 (en) 2024-10-02
BR112019002394B1 (pt) 2021-12-21
AU2021273642A1 (en) 2021-12-16
JP2022137288A (ja) 2022-09-21
KR20220098108A (ko) 2022-07-11
KR102607285B1 (ko) 2023-12-01
ES3000558T3 (en) 2025-02-28
EP3511340A4 (en) 2020-03-18
KR20230163339A (ko) 2023-11-30
US20230416325A1 (en) 2023-12-28
CN110267977A (zh) 2019-09-20
EP4470552A2 (en) 2024-12-04
AU2021273642B2 (en) 2025-03-13
MX386014B (es) 2025-03-18
SG11201901071TA (en) 2019-03-28
MX2019001651A (es) 2019-09-04
BR112019002394A2 (pt) 2019-06-04
MX2021010809A (es) 2021-10-01
CA3033475A1 (en) 2018-02-15
US10696722B2 (en) 2020-06-30
EP3511340A1 (en) 2019-07-17
US20200362005A1 (en) 2020-11-19
KR102416411B1 (ko) 2022-07-05
IL264692A (enExample) 2019-04-30
DK3511340T3 (da) 2025-01-02
IL264692B1 (en) 2025-08-01
AU2017310163A1 (en) 2019-03-21
KR20190134564A (ko) 2019-12-04
JP2021088601A (ja) 2021-06-10
US11692019B2 (en) 2023-07-04
ZA201900772B (en) 2023-07-26
JP7488854B2 (ja) 2024-05-22
EP4470552A3 (en) 2025-03-05
IL264692B2 (en) 2025-12-01
US11078249B2 (en) 2021-08-03
KR102652247B1 (ko) 2024-03-29
US20200362004A1 (en) 2020-11-19
US12358964B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
KR102652247B1 (ko) 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR101928981B1 (ko) 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
US12319725B2 (en) IL-2 mutant and application thereof
US20250236653A1 (en) Targeted low potency il-12 fc fusion proteins and uses thereof
HK40014568A (en) Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20170810

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190122

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190828

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20191125

Patent event code: PA01071R01D

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221017

Start annual number: 4

End annual number: 4